Phase 3 Prostate Cancer Trial, Recruiting NCT03903835 Sponsor: Karolinska Institutet Condition: Prostate Cancer
Back to Prostate Cancer

Phase 3 Prostate Cancer Trial, Recruiting

NCT03903835
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are a man who has been diagnosed with prostate cancer (confirmed by a tissue sample) that has spread to other parts of the body, and you are starting your first main treatment for this advanced stage
  • Your cancer has been found to have spread (to bones or other areas) through a bone scan, CT scan, or MRI
  • You are in good enough overall health, as judged by the trial doctor, to receive the treatments being tested in this trial
  • Your general ability to carry out daily activities falls within an acceptable range on a standard health scale (confirm with trial site)
  • Your blood tests show your organs and bone marrow are working well enough
  • Your blood protein (albumin) level is at or above a certain level (confirm with trial site)
  • You are able to understand the trial information and sign a consent form agreeing to take part

Who may not be able to join:

  • You have had another cancer in the past 5 years, except for certain common types of skin cancer
  • You have had a heart attack, unstable chest pain, heart surgery, stroke, or a mini-stroke, or have serious heart failure within the last 6 months
  • You have high blood pressure that is not under control
  • You have low blood pressure that is not under control
  • You have already received drug treatments (other than standard hormone therapy) for the castration-resistant stage of your prostate cancer before joining this trial
  • You have a serious ongoing medical condition that could put you at higher risk of harm or affect the trial results
  • You are unable to follow the trial's procedures and requirements
  • You are currently in another clinical trial that could conflict with this one, or have received an experimental treatment or had major surgery in the last 28 days
  • The trial doctor believes, for any reason, that taking part would put you at risk or affect the trial results
  • You have a medical condition — such as significant heart or liver disease — that would make it unsafe to use the treatments in this trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Henrik Grönberg, Professor, Karolinska Institutet

Phone: +46 8 52482576

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
1 February 2019
Est. completion
1 December 2026

Where this trial is recruiting

🇧🇪 Belgium 🇳🇴 Norway 🇸🇪 Sweden 🇨🇭 Switzerland

Primary endpoints

Progression free survival (PFS) in mCRPC; Progression free survival (PFS) in mHSPC

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov